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tdiponectin levels are associated with coronary
rtery disease across Caucasian and African-
merican ethnicity
UIJING LU, ALAN CHIEM, ERDEMBILEG ANUURAD, PETER J. HAVEL, THOMAS A. PEARSON,
ERNARD ORMSBY, and LARS BERGLUND
AVIS AND SACRAMENTO, CALIF, ROCHESTER, NY, AND CHANGSHA, CHINA
The hypothesis was tested that plasma levels of adiponectin would be associated
with coronary artery disease (CAD) across African-American and Caucasian eth-
nicity and gender. Adiponectin levels, cardiovascular risk factors, and extent of
CAD were measured in 453 subjects (173 African-American and 280 Caucasian
men and women). The distribution of adiponectin levels differed significantly be-
tween African-Americans and Caucasians (P< 0.0001). Among African-Americans,
the adiponectin distribution was skewed toward lower levels. For women, adi-
ponectin levels were higher among Caucasians compared with African-Americans
(P< 0.001), whereas no interethnic difference was observed for men. Irrespective of
ethnic group, subjects with CAD had lower levels of adiponectin than did subjects
without CAD. Adiponectin was negatively and significantly associated with waist–
hip ratio, body mass index, diastolic blood pressure, insulin level, and homeostasis
model assessment—insulin resistance in both ethnic groups. Among lipid parame-
ters, total cholesterol, triglyceride, and low-density lipoprotein cholesterol levels
were negatively correlated with adiponectin, whereas the high-density lipoprotein
cholesterol level correlated positively for both African-Americans and Caucasians.
In a multiple regression model, controlling for gender, ethnicity, and other CAD risk
factors, adiponectin levels were negatively associated with CAD (P < 0.05). The
results indicate that, across gender and ethnicity, low adiponectin levels may be an
independent risk factor for CAD. (Translational Research 2007;149:317–323)
Abbreviations: CAD  coronary artery disease; HDL  high-density lipoprotein; HOMA-IR 
homeostasis model assessment—insulin resistance; LDL  low-density lipoprotein; OR  odds
ratio; SD  standard deviation
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about 10 years ago, has prominent effects on
both lipid and carbohydrate metabolism, in-
luding increased lipid oxidation, decreased hepatic
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318 Lu et al June 2007n liver and skeletal muscle, leading to a reduced po-
ential for ectopic fat accumulation.4 Plasma levels of
diponectin are affected by age and lifestyle factors,
nd in addition, there is a sexual dimorphism, where
omen have higher levels than men.5,6 Decreased adi-
onectin levels are associated with the metabolic syn-
rome and conditions of insulin resistance.7,8 Further-
ore, it has been suggested that adiponectin may
nteract with genetic and environmental factors in the
evelopment of insulin resistance, the metabolic syn-
rome, and type 2 diabetes mellitus.9–12 In addition to
ts putative role in energy metabolism, adiponectin has
een suggested to affect the atherosclerotic process as it
ccumulates in injured vessel walls and influences
any components of the vessel wall.13–15
Results from clinical studies support the contention
hat adiponectin may have antiatherogenic properties,
nd that low adiponectin levels constitute a cardiovas-
ular risk factor. Hypoadiponectinemia has been ob-
erved in patients with coronary artery disease (CAD)
s well as in patients at increased risk for cardiovascu-
ar disease with obesity and diabetes mellitus.12,16–18
owever, an increase in adiponectin levels was asso-
iated with overall mortality in Caucasian patients un-
ergoing coronary angiography in a recent study.19
diponectin levels are regulated dynamically, as either
ubstantial weight reduction or administration of insu-
in sensitizers to patients with diabetes mellitus increase
irculating adiponectin levels.20,21 As several factors
otentially influencing adiponectin levels, such as high-
ensity lipoprotein (HDL) cholesterol, triglycerides,
besity, and hypertension differ markedly between Af-
ican-Americans and Caucasians,22,23 the hypothesis
as tested that adiponectin levels would be associated
ith CAD as determined by coronary angiography in
aucasian and African-American men and women. In
ddition, the role of adiponectin was explored in rela-
ion to other cardiovascular risk factors across gender
nd ethnicity.
ESEARCH DESIGN AND METHODS
Subjects. Subjects were recruited from a patient pop-
lation scheduled for diagnostic coronary arteriography
t either Harlem Hospital Center in New York City or
he Mary Imogene Bassett Hospital in Cooperstown,
Y.24,25 All consecutive patients scheduled for elective
oronary arteriography at the 2 sites between June 1993
nd April 1997 were approached. A total of 648 pa-
ients, 401 men and 247 women, ethnically self-identi-
ed as Caucasians (n  344), African-Americans (n 
32), or other (n  72) were enrolled. The recruitment
rocedure, including inclusion and exclusion criteria,
ave been described earlier.26,27 In this study, plasma
amples were available from 453 of the 576 Caucasians mnd African-Americans enrolled in the study (177 Cau-
asian men, 103 Caucasian women, 100 African-Amer-
can men, and 73 African-American women). The study
as approved by the Institutional Review Boards at
arlem Hospital, Bassett Healthcare, Columbia Uni-
ersity College of Physicians and Surgeons, and Uni-
ersity of California—Davis, and informed consent
as obtained from all participants.
Clinical and biochemical assessment. Fasting blood
amples were drawn approximately 2 to 4 h before the
atheterization procedure, and plasma samples were
tored at –80°C before analysis. Plasma adiponectin
evels were measured using a radioimmunoassay
Linco Research Inc., St. Louis, Mo) with intra-assay
nd interassay coefficients of variation of 5.5% and
.3%, respectively. Plasma total cholesterol, triglycer-
de, and HDL cholesterol were determined by standard
nzymatic procedures.28 The low-density lipoprotein
LDL) cholesterol levels were calculated in subjects
ith triglyceride levels 400 mg/dL with the formula
f Friedewald et al.29 Plasma insulin was measured
sing a commercial radioimmunoassay procedure (Di-
gnostic Products, Los Angeles, Calif). Homeostasis
odel assessment–insulin resistance (HOMA-IR) was
alculated using the updated model available from the
xford Centre for Endocrinology and Diabetes (Ox-
ord, UK).30,31 BMI was calculated as weight divided
y the square of height.
Coronary angiography The coronary angiograms
ere read by 2 experienced readers blinded to patient
dentity, the clinical diagnosis, and the lipoprotein re-
ults. The readers recorded the location and extent of
uminal narrowing for 15 segments of the major coro-
ary arteries.32 In the current study, patients were clas-
ified as having CAD if a stenosis of 50% was found
n at least 1 segment. Patients without CAD were
efined as having 50% stenosis in all segments.
Statistical analysis. Data are described as mean 
tandard deviation (SD) or as the median and interquar-
ile range as appropriate. As the plasma adiponectin
requency distribution was skewed in both Caucasians
nd African-Americans, we explored transformation of
diponectin levels using either logarithm or square root.
quare root transformation resulted in the most normal
istribution and was therefore used in subsequent anal-
sis. Levels of triglycerides, insulin, and HOMA-IR
ere log transformed to achieve normal distributions
efore statistical analysis. Group means were compared
sing the Student t-test. Differences in the distribution
f adiponectin levels between CAD and non-CAD sub-
ects for each ethnic group were analyzed using the
onparametric Kolmogorov–Smirnov test. Univariate
elationships between adiponectin levels and anthropo-
etric variables were described by the Pearson corre-
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Volume 149, Number 6 Lu et al 319ation coefficients. Multiple logistic regression analysis
as used to assess the association with case-control
tatus of the various known and potential risk factors.
lthough initially several potential variables were ex-
lored in this analysis, including established cardiovas-
ular risk factors significantly associated with CAD in
revious studies, the final model included only vari-
bles that were significantly associated with CAD in the
urrent dataset.
ESULTS
Characteristics of the subjects are shown in Table I.
he CAD group was older and had lower HDL choles-
erol and higher triglyceride, total cholesterol, LDL
holesterol, insulin, and glucose levels as compared
ith the non-CAD group. In addition, the waist–hip
atio and insulin resistance as estimated by HOMA-IR
ere higher in the CAD group.
The distribution of adiponectin levels differed be-
ween Caucasians and African-Americans (Fig 1).
mong African-Americans, the adiponectin distribu-
ion was skewed toward lower levels. The maximum
ifference in the cumulative adiponectin frequency be-
ween the 2 ethnic groups was 0.22 at an adiponectin
evel of 4.04, with a Kolmogorov–Smirnov statistic of
.291, P  0.0001, confirming a significant difference
n the interethnic adiponectin frequency distribution.
s observed in Fig 2, of the 4 gender/ ethnicity groups,
aucasian women had significantly higher median adi-
onectin levels compared with the 3 other groups (P 
able I. Clinical characteristics of subjects with
nd without CAD
CAD
(n  235)
Non-CAD
(n  218) P value
en/women 166/69 111/107
frican-American/
Caucasian
76/159 97/121
ge (years) 59.3  8.5 51.4 10.4 0.001
MI (kg/m2) 29.2  5.5 29.3 6.3 NS
aist–hip ratio 0.96 0.07 0.94  0.07 0.003
lucose (mmol/L) 7.4  3.7 6.7  3.5 0.030
nsulin (U/mL) 15.7 (9.5–28.2) 13.7 (8.9–22.2) 0.035
OMA-IR 4.3 (2.6–10.7) 3.4 (2.1–6.5) 0.010
holesterol (mg/dL) 203 43 189  39 0.001
riglyceride (mg/dL) 144 (106–216) 115 (86–162) 0.001
DL cholesterol
(mg/dL)
129  37 117  33 0.001
DL cholesterol
(mg/dL)
41  14 46  14 0.001
otes: Results expressed as means  SD, or for non-normally dis-
ributed variables as median (interquartile range). SI units given
ith brackets where appropriate.
bbreviation: NS, not significant..001). nAdiponectin levels were associated with cardiovas-
ular risk parameters across ethnicity. Adiponectin was
egatively associated with waist–hip ratio (P 0.016),
MI (P  0.0001), diastolic blood pressure (P 
.037), insulin level (P  0.001), and HOMA-IR (P
0.001). Among lipid parameters, total cholesterol (P
0.026), triglyceride (P  0.001), and LDL choles-
erol levels (P 0.007) were negatively correlated with
diponectin, whereas the HDL cholesterol level (P 
.001) correlated positively. No significant correlations
ere observed between adiponectin and age, systolic
lood pressure, or glucose.
Next the cumulative distribution of adiponectin lev-
ls was analyzed in subjects with and without CAD in
he 2 ethnic groups. As observed in Fig 3, subjects with
AD had lower levels than subjects without CAD,
rrespective of ethnicity. For both ethnic groups, differ-
nces between CAD and non-CAD subjects were ob-
erved over the entire span of adiponectin level. Fur-
hermore, differences between the CAD and the non-
AD subjects were similar for African-Americans and
aucasians. Thus, the maximum difference of the cu-
ulative adiponectin distribution between CAD and
on-CAD subjects in African-Americans and Cauca-
ians were 0.22 and 0.20, respectively.
To assess the independent association of adiponectin
evels with CAD, a multiple logistic regression was
nitially performed controlling for gender and ethnicity,
here adiponectin levels remained independently and
nversely associated with CAD [odds ratio (OR) 
.68, P  0.001]. Then a more comprehensive analysis
as performed adjusting for age, hypertension, smok-
ng, LDL cholesterol, ethnicity, BMI, diabetes mellitus,
nd HOMA-IR. As observed in Table II, adiponectin
evels remained significantly and independently in-
ersely associated with CAD (OR  0.58, P  0.003)
n the latter model. Other positive predictors for CAD
ere age (OR  1.10, P  0.001), gender (OR  2.10,
 0.017), hypertension (OR  2.06, P  0.029),
DL cholesterol (OR  1.01, P  0.011), ethnicity
OR  2.85, P  0.001), and diabetes mellitus (OR 
.07, P  0.001).
ISCUSSION
The relationship of adiponectin and CAD was exam-
ned in a biracial Caucasian and African-American
roup, where many predictors of adiponectin levels
iffer across ethnicity. The adiponectin level distribu-
ion differed significantly between Caucasians and Af-
ican-Americans. Caucasian women had significantly
igher adiponectin levels than the other 3 gender/eth-
icity groups. Furthermore, adjusting for gender, eth-
icity, and other CAD risk factors, lower circulating
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320 Lu et al June 2007evels of adiponectin were independently associated
ith CAD.
Compared with Caucasians, African-Americans had
skewed adiponectin distribution toward lower levels,
nd the largest difference in the cumulative frequency
as at adiponectin levels of about 4 g/mL. Among the
gender/ethnicity groups (African-American men and
omen, and Caucasian men and women), adiponectin
evels were higher among Caucasian women in keeping
ith previous reports of higher plasma adiponectin
evels in female subjects.33 However, African-Ameri-
Fig 1. Frequency distribution of adiponectin lev
adiponectin levels were reported.
ig 2. Adiponectin levels in 4 gender/ethnicity groups (African-
merican men and women and Caucasian men and women). Levels
re reported as medians and interquartile range. *P  0.001; Cauca-
ian women had different adiponectin levels compared with the other
groups.an women had levels similar to men. Previous studies mave demonstrated an effect of both obesity and eth-
icity on adiponectin levels in women, as levels were
ignificantly higher in Caucasian non-obese women
ompared with either non-obese African-American
omen or obese Caucasian or African-American
omen.34 These findings of lower adiponectin levels
mong African-American women compared with Cau-
asian women are in agreement with these results.
urthermore, a lack of difference is reported here
cross gender among African-Americans. However, it
s possible that a difference in body fat distribution
cross ethnicity might be contributory. Arguing against
his possibility, there was no significant difference in
MI levels or waist–hip ratio between the 2 ethnicity/
ender groups, although differences in central/visceral
besity cannot totally be ruled out. Furthermore, other
tudies have also reported differences in adiponectin
evels among various ethnic groups. Thus, pregnant
omen of South Asian descent exhibited significantly
educed plasma adiponectin concentrations compared
ith pregnant Caucasian women.35 Furthermore,
lasma adiponectin levels were lower in Pima Indians
s compared with Caucasians.36
The association between adiponectin and CAD was
ndependent of gender, BMI, and ethnicity, and of
stablished cardiovascular risk factors such as smoking,
ypertension, and LDL cholesterol. The demonstration
hat the association of adiponectin with CAD was in-
ependent of established risk factors suggests the pos-
ibility of differences in mechanisms underlying the
mpact of adiponectin compared with those other risk
actors. In support of this, recent studies reported that
diponectin has anti-atherogenic properties, as adi-
onectin modulates the inflammatory response of en-
othelial cells,13 suppresses foam cell formation,37 and
uppresses the proliferation and migration of smooth
ucasians and African-Americans. Untransformeduscle cells.38 Adiponectin has also been reported to
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Volume 149, Number 6 Lu et al 321e associated with insulin resistance, and high adi-
onectin levels protect against the impairment of glu-
ose metabolism in obese subjects and reduces the risk
f developing type 2 diabetes mellitus.8,39
In this study, associations between adiponectin and
stablished cardiovascular risk factor and degree of
oronary artery disease in 2 ethnic groups with pro-
ounced differences in risk factor spectrum were ex-
lored. Notably, the relative distribution pattern of adi-
onectin in CAD and non-CAD subjects was similar for
frican-Americans and Caucasians. Thus, the differ-
nces in the cumulative adiponectin distribution be-
ween CAD and non-CAD subjects were 0.22 for Af-
Fig 3. Cumulative distribution of adiponectin leve
coronary artery disease.
able II. Multiple logistic regression analysis with
AD
Variables OR 95% CI P value
diponectin (g/mL) 0.58 0.41–0.84 0.003
ge 1.10 1.06–1.14 0.001
ender 2.10 1.08–3.94 0.017
ypertension 2.06 1.00–3.53 0.029
moking 1.87 0.94–1.04 NS
DL-C (per 40 mg/dL) 1.01 1.58–5.96 0.011
ace/ethnicity 2.85 1.14–3.85 0.001
MI 0.99 1.00–1.02 NS
iabetes mellitus 3.07 1.52–5.34 0.001
OMA-IR 0.99 0.98–1.01 NS
ote: Results are reported for beta coefficient.
bbreviation: NS, not significant.ican-Americans and 0.20 for Caucasians. This might wuggest that the impact of adiponectin in relation to
AD might be similar in the 2 groups.
Despite a negative association found between adi-
onectin levels and CAD reported in this as well as
everal other studies, an association between increased
diponectin levels and mortality among subjects under-
oing coronary angiography was recently reported.19 It
s noteworthy also that, in the latter study, adiponectin
evels were negatively associated with signs of cardio-
ascular disease, ie, luminal narrowing,19 which is in
greement with the current findings. This raises the
ossibility that adiponectin, despite its association with
nti-atherogenicity, may be a marker of additional car-
iovascular risk factors. These intriguing results indi-
ate the need for a more comprehensive understanding
f the role of adiponectin as a disease modulator.
Potential limitations of the current study need to be
iscussed. Subjects in this study were recruited from
atients scheduled for elective coronary angiography,
nd therefore, they may not be representative of the
opulation at large. However, none of the patients had
cute coronary symptoms, and clinical and laboratory
arameters were in agreement with differences gener-
lly observed between African-American and Cauca-
ian populations from other studies. Thus, in previous
tudies, differences found in population-based studies
ave been verified between Caucasians and African-
mericans in lipid and lipoprotein levels as well as in
enotype frequencies.24,40–42 Furthermore, this study
casians and African-Americans with and withoutls in Cauas limited to measurement of plasma adiponectin
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322 Lu et al June 2007evels, and it did not assess whether high molecular
orms of this protein would be associated with cardio-
ascular disease.
In conclusion, these results indicate that plasma adi-
onectin levels differed among Caucasians and Afri-
an-Americans, and that levels were higher in Cauca-
ian women compared with the other 3 gender/ethnicity
roups. The finding of an inverse association between
diponectin and CAD in both ethnic groups studied
uggests that low adiponectin levels may be a risk
actor for cardiovascular disease in both Caucasians
nd African-Americans. In view of the apparent con-
radictory findings regarding a potential role of adi-
onectin as a risk factor for cardiovascular disease or
verall mortality, more prospective studies across eth-
ic groups are needed.
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